Media Centre
Press Releases
27, May, 2022
Janssen Responds to NICE Assessment for SPRAVATO®▼ (Esketamine) Nasal Spray for Treatment-Resistant Major Depressive Disorder
01, February, 2022
BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) Authorised in Great Britain for the Maintenance Treatment of Schizophrenia in Adults
Quick Links
FOLLOW US
Janssen UK
@JanssenUK
-
We are pleased to see this year’s @ConfedExpo highlighting health inequalities improvement as one of its priorities… https://t.co/QPNDBNZzjN
9 months 2 weeks ago